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Primary intracranial sarcomas with DICER1 mutation often 
contain prominent eosinophilic cytoplasmic globules and can 
occur in the setting of neurofibromatosis type 1
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A broad spectrum of primary sarcoma subtypes are now recognized to occur intracranially, 
presumably arising from mesenchymal progenitor cells within the meningeal covering of the 
brain and along perivascular Virchow-Robin spaces. Here we report the clinical, radiologic, 
histologic, and molecular features of three patients with intracranial sarcomas that are 
unified by the presence of primary intracranial location with meningeal involvement, 
pleomorphic morphology, high proliferation index, prominent eosinophilic cytoplasmic 
globules, focal immunophenotypic evidence of myogenic differentiation, and the 
combination of DICER1 and TP53 mutations, along with ATRX inactivation and genetic 
alterations causing activation of the MAP kinase signaling pathway. One patient has 
neurofibromatosis type 1 (NF1) with multiple cutaneous neurofibromas, cafe-au-lait 
macules, an optic pathway glioma, and other brain parenchymal lesions characteristic of 
NF1. This patient was found to have a heterozygous germline nonsense mutation in the NF1 
tumor suppressor gene, along with a second somatic mutation of NF1 in the primary 
intracranial sarcoma, indicating that this tumor arose due to biallelic NF1 gene inactivation. 
Genome-wide methylation profiling performed on two of the cases revealed that they 
clustered with the recently described group of tumors termed “primary intracranial spindle 
cell sarcoma with rhabdomyosarcoma-like features, DICER1 mutant” [7]. However, while 
the three tumors in our cohort demonstrate myogenic differentiation as evidenced by focal 
desmin immunopositivity, none contain identifiable rhabdomyoblasts, they uniformly lack 
myogenin expression, and are all morphologically best characterized as pleomorphic rather 
than predominantly spindled. Thus, this patient cohort expands the histologic spectrum and 
association with familial tumor predisposition syndromes of the primary intracranial 
sarcomas that cluster with this new methylation subgroup. As such, we suggest a broader 
designation for this new proposed entity: “Primary intracranial sarcoma, DICER1-mutant”.
The one female and two male patients ranged in age at time of initial surgery from 11–20 
years (Figure 1a). Patients #1 and #3 had been previously healthy and had no family history 
of cancer or cutaneous, visceral, or brain lesions other than the primary intracranial 
sarcomas suggestive of a tumor predisposition syndrome. Patient #2 had a clinical diagnosis 
of NF1 with multiple cutaneous neurofibromas, café-au-lait macules, an optic pathway 
glioma, and multifocal T2 signal abnormality within the thalamus, brainstem, and 
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cerebellum (Supplemental Figure 1 [Online Resource 1]). The patients had initially 
presented with either seizure or headache. Brain imaging demonstrated complex, solid and 
cystic, heterogeneously enhancing masses centered within the frontal or parietal lobes with 
meningeal involvement in all three patients (Figure 1b, Supplemental Figure 1 [Online 
Resource 1], and Supplemental Table 1 [Online Resource 2]). All tumors demonstrated 
evidence of prior hemorrhage and were associated with peritumoral edema. Surgical 
resection was performed for each patient.
Histologic analysis of the three tumors revealed sarcomatous neoplasms that were highly 
cellular with brisk mitotic activity, foci of necrosis, and intratumoral hemorrhage. 
Morphology was variable but predominantly consisted of sheets of pleomorphic tumor cells 
without a discernible growth pattern. A notable histologic feature shared by all three cases 
was the presence of prominent variablysized brightly eosinophilic cytoplasmic globules 
(Figure 1c and Supplemental Figures 2-4 [Online Resource 1]). Similar eosinophilic 
cytoplasmic globules were present at least focally in the majority of the 22 tumors reported 
by Koelsche et al [7], Case #3 contained a small focus of cartilaginous differentiation. 
Rhabdomyoblasts with cytoplasmic striations (“strap cells”) were not identifiable in any of 
the cases, nor was production of osteoid matrix or bone. No associated diffuse glioma was 
seen in any case to warrant classification as gliosarcoma, although the possibility of a 
sarcoma-predominant gliosarcoma was considered a diagnostic possibility prior to molecular 
profiling. Reticulin staining demonstrated abundant intercellular basement membrane 
deposition in each tumor. Immunohistochemistry demonstrated focal or patchy staining for 
desmin in all cases, but no myogenin or smooth muscle actin expression was observed 
(Figure 1d and Supplemental Figures 2-4). Tumor cells were uniformly negative for GFAP, 
OLIG2, S-100, SOX10, and cytokeratin immunostaining. The Ki67 labeling index was 
greater than 50% in all three cases. Tumors #1 and #3 demonstrated strong nuclear p53 
positivity in the majority of tumor cells, as well as loss of ATRX expression.
In order to assist with diagnostic classification, comprehensive genetic profiling was 
performed on genomic DNA extracted from formalin-fixed, paraffin-embedded tumor tissue 
from the three patients, as well as a peripheral blood sample from patient #2, using the 
UCSF500 Cancer Panel, which assesses approximately 500 cancer-associated genes for 
mutations, copy number alterations, and structural variants, as well as evaluation of 
chromosomal copy number changes, microsatellite stability, and somatic mutation burden 
(Supplementary Table 2 [Online Resource 2] and refs. 3, 4, 5, 8, 9, 10, 11, 12). All three 
cases demonstrated hotspot missense mutations in exons 24 or 25 of the DICER1 gene 
(p.E1705K, p.G1809R, and p.E1813K) located within the Ribonuclease III domain near the 
C-terminus of the encoded microRNA processing enzyme (Supplemental Table 3 [Online 
Resource 2]), which have been recurrently seen as confirmed somatic mutations in numerous 
cystic nephromas, Sertoli-Leydig cell tumors, and other neoplasms known to be driven by 
DICER1 mutation (Catalog Of Somatic Mutations In Cancer [COSMIC] database, version 
87 release). The DICER1 mutation in the tumor from patient #1 was homozygous due to 
copy-neutral loss of heterozygosity of chromosome 14q that eliminated the remaining 
wildtype allele. In the tumors from patients #2 and #3, there was a second splice site 
mutation in the DICER1 gene (c.2436+1G>A and c.5365-1G>A) likely to be present in 
trans and causing inactivation of the remaining wildtype allele. Such inactivating mutations 
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affecting one allele together with a hotspot missense mutation affecting the other allele are 
commonly seen in tumor types known to be driven by DICER1 mutations [2]. Additionally, 
all three cases demonstrated inactivating mutations affecting the TP53 tumor suppressor 
gene (p.W91*, p.C238F, and p.E258K) accompanied by loss of the remaining wildtype 
alleles. Two cases demonstrated inactivation of the ATRX tumor suppressor gene, one with 
deep deletion and one with a nonsense mutation (p.W263*). Lastly, each case harbored 
pathogenic mutations predicted to cause activation of the MAP kinase signaling pathway. 
The tumor from patient #1 harbored an activating hotspot mutation in the KRAS oncogene 
(p.G12D), and the tumor from patient #3 harbored a hotspot missense mutation in the 
PDGFRA oncogene (p.D842Y) located within the intracellular tyrosine kinase domain that 
has been recurrently seen as a confirmed somatic mutation in numerous gastrointestinal 
stromal tumors (COSMIC database, version 87 release). Patient #2 was found to harbor a 
heterozygous truncating nonsense mutation in NF1 tumor suppressor gene (p.R192*) in the 
germline, genetically confirming the clinical diagnosis of NF1. A second somatic missense 
mutation in the NF1 gene (p.D2632G) was seen in the tumor, indicating that the sarcoma 
likely arose, at least in part, due to biallelic NF1 inactivation. As tumor tissue only without a 
paired normal sample was sequenced for patients #1 and #3, the somatic versus germline 
status of the identified DICER1 and TP53 mutations could not be determined, but the 
DICER1 and TP53 mutations in patient #2 were both confirmed to be somatic (tumor-
specific). All three tumors demonstrated markedly aneuploid genomes with partial gains and 
losses involving portions of most chromosomes (Supplementary Figure 5 [Online Resource 
1]). Genome-wide DNA methylation profiling was performed on cases #1 and #2 as 
previously described [1, 6] using the Illumina MethylationEPIC BeadChip (850k array) to 
further characterize these primary intracranial sarcomas with myogenic differentiation and 
DICER1 mutation. Unsupervised clustering of DNA methylation patterns demonstrated that 
both cases clustered with the recently described group of tumors termed “primary 
intracranial spindle cell sarcoma with rhabdomyosarcoma-like features, DICER1 mutant” – 
calibrated score for case #1 was 0.84 and for case #2 was 0.99 (Supplementary Figure 6 
[Online Resource 1]).
Following gross total resection, patient #1 was treated with craniospinal radiation and 
adjuvant chemotherapy with vincristine. He was alive without evidence of disease 
recurrence at last clinical follow-up approximately six weeks after initial resection. 
Following gross total resection, patient #2 was treated with cranial radiation and adjuvant 
chemotherapy with temozolomide. Disease recurrence adjacent to the resection cavity in the 
left parietal lobe was seen on follow-up imaging at four years after initial resection, and a 
second resection was recently performed confirming recurrent pleomorphic sarcoma with 
myogenic differentiation and DICER1 mutation. Patient #3 was only recently diagnosed and 
is currently beginning adjuvant therapy.
Overall, this series of three primary intracranial sarcomas has significant similarities with 
the group of “primary intracranial spindle cell sarcomas with rhabdomyosarcoma-like 
features, DICER1 mutant” that were recently reported including primary intracranial 
location, immunophenotypic evidence of focal myogenic differentiation, overlapping 
genome-wide methylation profile, co-occurring DICER1 and TP53 mutations, and 
alterations activating the MAP kinase signaling pathway. However, the tumors in our series 
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have morphology best characterized as pleomorphic rather than spindled, uniformly lack 
rhabdomyoblasts and myogenin expression, and demonstrate frequent ATRX inactivation. 
As these tumors are all likely to be variants of the same entity we propose the broader 
nomenclature of “Primary intracranial sarcoma, DICER1-mutant”. Though unlikely to be 
specific, a histologic feature uniformly observed in our case series that should suggest 
consideration of this tumor entity in an intracranial sarcomatous neoplasm is the presence of 
prominent eosinophilic cytoplasmic globules. In addition to the previously reported 
association with the DICER1 pleuropulmonary blastoma tumor syndrome, we identify that 
these primary intracranial sarcomas with DICER1 mutation can also occur in the setting of 
NF1, thereby extending the tumor spectrum associated with this common familial tumor 
syndrome.
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Figure 1. 
Clinical, radiologic, histologic, and molecular features of three patients with primary 
intracranial pleomorphic sarcomas with myogenic differentiation and DICER1 mutation. a, 
Clinical features and pathogenic molecular alterations identified. b, Pre-operative T1-
weighted post-contrast MR images. c, Representative images from H&E stained sections 
showing pleomorphic sarcomas with brisk mitotic activity and prominent eosinophilic 
cytoplasmic globules. d, Summary of reticulin staining and immunohistochemical results.
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